Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Keytruda (pembrolizumab) in the treatment of patients with endometrial cancer
- Cibinqo (abrocitinib) in the treatment of patients with atopic dermatitis
- Lynparza Imfinzi (durvalumabum) in the treatment of patients with endometrial cancer
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
